You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY20 is not expected to be complete until September, 2021.

  1. High throughput multiplexed characterization and modeling of antibody antigen binding with application to HSV

    SBC: Carterra, Inc.            Topic: NIAID

    Abstract All therapeutic antibodies and most vaccines critically depend on the ability of antibodies to specifically recognize particular antigens consequently detailed characterization of antibody antigen binding can provide invaluable information to understand and guide development Unfortunately due to the time and expense required atomic resolution structure determination is typically use ...

    SBIR Phase I 2017 Department of Health and Human ServicesNational Institutes of Health
  2. Development of a DNA Aptamer Based Electrochemical Assay for Acetazolamide in Urine Using a Handheld Biosensor for Compliance Validation in Clinical Drug Trials

    SBC: ApolloDx , LLC            Topic: NIDA

    Development of a DNA Aptamer Based Electrochemical Assay for Acetazolamide in Urine Using a Handheld Biosensor for Compliance Validation in Clinical Drug Trials Thirty to over eighty percent of patients enrolled in pharmaceutical clinical trials do not comply with trial protocols by discarding the drug under investigation or not using the proper dosages This common practice compromises the medica ...

    SBIR Phase I 2017 Department of Health and Human ServicesNational Institutes of Health
  3. Biomaterials for mRNA based cellular reprogramming

    SBC: Stem Pharm, Incorporated            Topic: 100

    Project Summary Abstract Induced pluripotent stem cells iPSCs hold great promise in the areas of disease modeling and regenerative medicine and as a result have unique commercial potential There are currently more than ongoing clinical trials in stem cell therapies including the first in human trial using human iPSC derived retinal pigment epithelial cells to treat ...

    SBIR Phase I 2017 Department of Health and Human ServicesNational Institutes of Health
  4. HTS Assays for Targeting the cGAS STING Pathway in Autoimmune Diseases and Cancer

    SBC: Bellbrook Labs, LLC            Topic: 300

    SUMMARY Cytoplasmic nucleic acids alert the immune system to invading pathogens and trigger a robust type I interferon IFN response via activation of the STING stimulator of interferon genes receptor The sensor for cytoplasmic nucleic acids was recently discovered to be a cyclic GMP AMP synthase which produces a unique cyclic dinucleotide second messenger cGAMP that serves as an agonist fo ...

    SBIR Phase I 2017 Department of Health and Human ServicesNational Institutes of Health
  5. Tessa Sleep Quality Monitoring

    SBC: EPITEL, INC.            Topic: NHLBI

    ABSTRACT TessaTM is validated medical device wearable capable of providing clinical sleep quality metrics for multiple nights to assess the efficacy of a sleep disorder treatment Tessa records the forehead EEG to stage sleep in an automated report that tracks changes in sleep architecture before and after a treatment for many sleep disorders such as obstructive sleep apnea and insomnia There is ...

    SBIR Phase I 2017 Department of Health and Human ServicesNational Institutes of Health
  6. High Fidelity Linear MicroVector to Clone Complex Problematic and Large DNAs

    SBC: VARIGEN BIOSCIENCES CORPORATION            Topic: 200

    The goal of this research is to dramatically improve the ability to clone and analyze large and unstable DNA fragments We propose to develop a novel linear cloning vector to maximize stability of cloned DNA in the bacterial host The vector will use the replication proteins of the phage Phi to achieve the highest accuracy of replication for all DNA inserts including AT rich repetitive or str ...

    SBIR Phase I 2017 Department of Health and Human ServicesNational Institutes of Health
  7. Automation of MicroC as a CDx for myeloma therapies

    SBC: Lynx Biosciences, Inc.            Topic: 102

    Multiple myeloma MM is a debilitating and currently incurable hematological malignancy While the median survival has increased to years MM patients ultimately relapse and become resistant to therapy Once they reach this stage it is often a trial and error process until an effective therapy can be found Furthermore the MM bone marrow tumor microenvironment plays a significant role in ...

    SBIR Phase I 2017 Department of Health and Human ServicesNational Institutes of Health
  8. IMMEDIATE FIT USING INNOVATIVE TECHNOLOGY PROSTHETIC SYSTEMS

    SBC: IFIT PROSTHETICS, LLC            Topic: N

    ABSTRACT The principal business interestiFIT Prosthetics LLCwith STTR fundingcreated a new transtibial prosthetic device and demonstrated its safetycomfortand functionIn contrast to conventionally made prosthetic limbsthe iFIT prosthesis is easily fit and aligned on the residual limb in a single sessionDue to its substantial adjustability and customized inner linerthe iFIT device is a comfortable ...

    SBIR Phase II 2017 Department of Health and Human ServicesNational Institutes of Health
  9. Novel Continuous Esophageal Pressure Monitoring Catheter with Feeding Tube

    SBC: RUSH RIVER RESEARCH CORPORATION            Topic: NICHD

    PROJECT SUMMARY ABSTRACT Over US adults and children are on mechanical ventilators in intensive care units each year While major advancements in ventilator devices have improved outcomes for critically ill patients current ventilator practice is predominately based on measurements of airway pressure The more relevant pressure particularly to determine if mechanical ventilation is causi ...

    SBIR Phase I 2017 Department of Health and Human ServicesNational Institutes of Health
  10. Therapeutic D-peptide Inhibitor of HIV Entry

    SBC: NAVIGEN, INC.            Topic: R

    PROJECT SUMMARYWhile modern HIV combination therapy has transformed HIV into a manageable chronic infection for many patientsHIV AIDS remains a formidable global epidemicDespite the effectiveness of combining drugs from different classesside effects and drug resistance remain serious concerns for these life long therapiesThusthere is an enduring need for novel HIV inhibitors with new mechanisms of ...

    SBIR Phase II 2017 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government